

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code : 3692)**

### **VOLUNTARY ANNOUNCEMENT**

#### **LICENSING AGREEMENT WITH OLIX PHARMACEUTICALS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**” or “**Hansoh**”) is pleased to announce that on October 11, 2021, Hansoh (Shanghai) Health Technology Co., Ltd. (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Ltd. (江蘇豪森藥業集團有限公司) (collectively, the “**Licensees**”), each a wholly-owned subsidiary of the Company, have entered into an exclusive license and collaboration agreement (the “**Licensing Agreement**”) with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) (“**OliX Pharmaceuticals**”).

Pursuant to the Licensing Agreement, OliX Pharmaceuticals will use its GalNAc-asiRNA platform technology to discover lead compounds and secure development candidates for targets in cardiovascular, metabolic, and other diseases associated with the liver. Hansoh will have the exclusive commercial rights to these therapeutics in China (including Hong Kong, Macau and Taiwan) (the “**Territory**”) and OliX Pharmaceuticals will have the rights in the rest of the world. OliX Pharmaceuticals will receive initial upfront payment of US\$6.5 million with up to US\$450 million plus royalties based on key milestones.

The Company is of the view that with OliX Pharmaceuticals’ leading position in siRNA development with an established clinical stage portfolio, it is expected that the Company will be able to utilize their innovative technology platform in development process to focus on liver-based targets that are implicated in areas including cardiovascular, metabolic and other diseases with an aim to address a broad range of unmet medical needs in the PRC. OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. OliX Pharmaceuticals is a company listed on the Korea Stock Exchange (KOSDAQ: 226950).

To the best knowledge and belief of the Company, OliX Pharmaceuticals is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, October 12, 2021

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*